A FIRST-IN-HUMAN SINGLE-DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF LY2165766 INCLUDING BRAIN DOPAMINE D2 RECEPTOR OCCUPANCY BY POSITRON EMISSION TOMOGRAPHY (PET)

A FIRST-IN-HUMAN SINGLE-DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF LY2165766 INCLUDING BRAIN DOPAMINE D2 RECEPTOR OCCUPANCY BY POSITRON EMISSION TOMOGRAPHY (PET) - LY2165766 SDSS/PET study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON33530

Enrollment

Registered

2008-09-04

Start date

2008-10-12

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

zie hierboven

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: healthy male Part A: 18 - 65 year. Part B: 35 - 65 year Part C: 35 - 65 year

Exclusion criteria

Exclusion criteria: Relevant disease in medical history

Design outcomes

Primary

Measure	Time frame
zie hierboven	—

Secondary

Measure	Time frame
zie hierboven	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)